



IFW

PATENT
Attorney Docket No. 056291-5282

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **BUDD HAEBERLEIN et al.**)
Application No.: **10/577,357**) Group Art Unit: *Unassigned*
Filed: **April 28, 2006**) Examiner: *Unassigned*
For: **USE OF SULFONAMIDE COMPOUNDS**)
FOR THE TREATMENT OF DIABETES)
AND/OR OBESITY) Date: **August 15, 2006**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of a U.S. Patent, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law,

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted
Morgan Lewis & Bockius LLP



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: August 15, 2006
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>  PTO Form 1449 August 15, 2006	Attorney Docket No. 056291-5282	Application No. 10/577,357
	Applicants: BUDD HAEBERLEIN <i>et al.</i>	
	Filing Date: April 28, 2006	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 5,491,172	February 13, 1996	Lee et al.	514	602	April 13, 1994

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
2.	WO 94/26702	November 24, 1994	WIPO			
3.	WO 2006/064189	June 22, 2006	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

4.	Anderson et al. "Identification of a Form of Acyl-CoA:Cholesterol Acyltransferase Specific to Liver and Intestine in Nonhuman Primates" <i>J Biol Chem</i> 273(41):26747-26754 (1998)
5.	Brown and Goldstein "Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis" <i>Annu Rev Biochem.</i> 52:223-261 (1983)
6.	Burnett and Huff "Avasimibe Pfizer" <i>Curr Opin Investig Drugs</i> 3(9):1328-1333 (2002)
7.	Cases et al. "ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase" <i>J Biol Chem</i> 273(41):26755-26764 (1998)
8.	Cases et al. "Cloning of DGAT2, a Second Mammalian Diacylglycerol Acyltransferase, and Related Family Members" <i>J. Biol. Chem.</i> 276(42):38870-38876 (2001)
9.	Cases et al. "Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis" <i>Proc Natl Acad Sci U S A.</i> 95(22):13018-13023 (1998)
10.	Chang et al. "Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells" <i>J. Biol. Chem.</i> 268(28):20747-20755 (1993)
11.	Chen et al. "Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1" <i>J. Clin. Invest.</i> 111(11):1715-1722 (2003)
12.	Coleman "Diacylglycerol acyltransferase and monoacylglycerol acyltransferase from liver and intestine" <i>Methods in Enzymology</i> 209:98-104 (1992)
13.	Field and Salome "Effect of dietary fat saturation, cholesterol and cholestyramine on acyl-CoA: cholesterol acyltransferase activity in rabbit intestinal microsomes" <i>Biochimica et Biophysica Acta</i> 712(3):557-570 (1982)
14.	Insull Jr. et al. "Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia" <i>Atherosclerosis</i> 157(1):137-144 (2001)
15.	Lehner and Kuksis "Biosynthesis of triacylglycerols" <i>Prog Lipid Res.</i> 35(2):169-201 (1996)
16.	Oelkers et al. "Characterization of Two Human Genes Encoding Acyl Coenzyme A:Cholesterol Acyltransferase-related Enzymes" <i>J Biol Chem</i> 273(41):26765-26771 (1998)
17.	Smith et al. "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat" <i>Nature Genetics</i> 25:87-90 (2000)
18.	Yen et al. "Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase" <i>Proc Natl Acad Sci U S A.</i> 99(13):8512-8517 (2002)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.